by Caroline Perry, Harvard University A new startup, i2O Therapeutics, has launched to commercialize innovations developed at Harvard University that may one day enable patients and clinicians to give up syringes in favor of pills. Using ionic liquid technologies developed in the lab of Harvard bioengineer Samir Mitragotri, biologic therapies that would normally need to...
